2-Thiopyrimidine/chalcone hybrids: design, synthesis, ADMET prediction, and anticancer evaluation as STAT3/STAT5a inhibitors

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics. CA Cancer J Clin 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Rao YK, Fang SH, Tzeng YM. Differential effects of synthesized 2′-oxygenated chalcone derivatives: modulation of human cell cycle phase distribution. Bioorg Med Chem 2004;12:2679–86.
   PubMed Web of Science ®Google Scholar
• Roco A, Quinones L, Acevedo C, et al. Situacion del cancer en Chile 2000–2010. Cuad Med Social 2013;53:83–94.
   Google Scholar
• Rajak H, Deshmukh R, Veerasamy R, et al. Novel semicarbazones based 25-disubstituted-1,3,4-oxadiazoles: one more step towards establishing four binding site pharmacophoric model hypothesis for anticonvulsant activity. Bioorg Med Chem Lett 2010;20:4168–72.
   PubMed Web of Science ®Google Scholar
• Marmol I, Sanchez-De-Diego C, Dieste AP, et al. Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. Int J Mol Sci 2017;18:E197.
   PubMed Web of Science ®Google Scholar
• Stewart B, Wild C. World cancer report 2014. World Health Organization; 2014.
   Google Scholar
• Sawyers CL, Denny CT, Witte ON. Leukemia and the disruption of normal hematopoiesis. Cell 1991;64:337–50.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Schneeweiss M, Eisenwort G, et al. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. Haematologica 2017;102:1519–29.
   PubMed Web of Science ®Google Scholar
• Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002;43:1221–8.
   PubMed Web of Science ®Google Scholar
• Ghiaur G, Wroblewski M, Loges S. Acute myelogenous leukemia and its microenvironment: a molecular conversation. Semin Hematol 2015;52:200–6.
   PubMed Web of Science ®Google Scholar
• Bosc C, Selak MA, Sarry J-E. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab 2017;26:705–7.
   PubMed Web of Science ®Google Scholar
• Coolbrandt A, Van den Heede K, Vanhove E, et al. Immediate versus delayed self-reporting of symptoms and side effects during chemotherapy: does timing matter? Eur J Oncol Nurs 2011;15:130–6.
   PubMed Web of Science ®Google Scholar
• McMurray JS, Ren Z, David C, et al. Inhibitors of signal transducer and activator of transcription 3. US 0010428 A1; 2007.
   Google Scholar
• Mandal PK, Gao F, Lu Z, et al. Potent and selective phosphopeptide mimetic prodrugs targeted to the src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 2011;54:3549–63.
   PubMed Web of Science ®Google Scholar
• Turkson J, Gunning PT. 2-(9h-Purin-9-yl) acetic acid analogues as inhibitors of STAT proteins: University of Central Florida Research Foundation, University of Toronto Mississauga. Patent WO 163424 A2; 2011.
   Google Scholar
• Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of STAT3, identified through structure-based virtual screening, induces antitumour activity. Proc Natl Acad Sci USA 2007;104:7391–6.
   PubMed Web of Science ®Google Scholar
• Segatto I, Baldassarre G, Belletti B. STAT3 in breast cancer onset and progression: a matter of time and context. Int J Mol Sci 2018;19:2818–27.
   Google Scholar
• Furqan M, Mukhi N, Lee B, et al. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res 2013;1:5–15.
   PubMedGoogle Scholar
• Ping-Shan L, David AR, Ahmed MA, et al. A STAT inhibitor patent review: progress since 2011. Expert Opin Ther Patents 2015;25:12–37.
   Google Scholar
• Furqan M, Akinleye A, Mukhi N, et al. STAT inhibitors for cancer therapy. J Hematol Oncol 2013;6:90.
   PubMed Web of Science ®Google Scholar
• Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945–54.
   PubMed Web of Science ®Google Scholar
• Weaver AM, Silva CM. Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res 2007;9:R79–89.
   PubMed Web of Science ®Google Scholar
• Jatiani SS, Baker SJ, Silverman LR, et al. JAK/STAT pathways in cytokine signaling and myelo-proliferative disorders: approaches for targeted therapies. Genes Cancer 2011;1:979–93.
   Google Scholar
• Fathi MAA, Abd El-Hafeez AA, Abdelhamid D, et al. 1,3,4-Oxadiazole/chalcone hybrids: design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities. Bioorg Chem 2019;84:150–63.
   PubMed Web of Science ®Google Scholar
• Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat Rev Cancer 2004;4:97–105.
   PubMed Web of Science ®Google Scholar
• Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts STAT3 SH2 domain-phosphotyrosine interactions and STAT3-dependent tumor processes. Biochem Pharmacol 2010;79:1398–409.
   PubMed Web of Science ®Google Scholar
• Li PK, Li C, Lin J, et al. Curcumin analogs as dual JAK2/STAT3 Inhibitors and methods of making and using the same. The Ohio State University Research Foundation. US 0053208 A1; 2012.
   Google Scholar
• Novilla A, Mustofa M, Astuti I, et al. Cytotoxic activity of methoxy-4′-amino chalcone derivatives against leukemia cell lines. Mol Cell Biomed Sci 2019;3:34–41.
   Google Scholar
• Bagul C, Rao GK, Makani VKK, et al. Synthesis and biological evaluation of chalcone linked pyrazolo[1,5-a]pyrimidines as potential anticancer agents. Med Chem Commun 2017;8:1810–6.
   Google Scholar
• Page BDG, Khoury H, Laister RC, et al. Small molecule STAT5-SH2 domain inhibitors exhibit potent antileukemia activity. J Med Chem 2012;55:1047–55.
   PubMed Web of Science ®Google Scholar
• Ahmed NM, Mohamed MS. Synthesis and biological value of thiouracils and fused thiouracils (a review). J Adv Pharm Res 2017;1:75–88.
   Google Scholar
• Prachayasittikul S, Worachartcheewan A, Nantasenamat C, et al. Synthesis and structure activity relationship of 2-thiopyrimidine-4-one analogs as antimicrobial and anticancer agents. Eur J Med Chem 2011;46:738–42.
   PubMed Web of Science ®Google Scholar
• Sondhi SM, Goyal RN, Lahoti AM, et al. Synthesis and biological evaluation of 2-thiopyrimidine derivatives. Bioorg Med Chem 2005;13:3185–95.
   PubMed Web of Science ®Google Scholar
• Yuh-Wen H, Maw CS. Thioxopyrimidine in heterocyclic synthesis I: synthesis of some novel 6-(heteroatom-substituted)-(thio)pyrimidine derivatives. J Chem 2013;1:1–15.
   Google Scholar
• Angelo R, Andre S, Silvia S, et al. Synthesis and antiproliferative activity of basic thioanalogues of merbarone. Bioorg Med Chem 2003;11:2575–89.
   PubMed Web of Science ®Google Scholar
• Chen H, Tsalkova T, Mei FC, et al. 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP. Bioorg Med Chem Lett 2012;22:4038–43.
   PubMed Web of Science ®Google Scholar
• Oluropo CA, Olugbeminiyi OF, Adamson SF, et al. Synthesis and in-vitro cytotoxicity evaluation of some fluorinated hexahydropyrimidine derivatives. Bioorg Med Chem Lett 2011;21:989–92.
   PubMed Web of Science ®Google Scholar
• Mosaad SM, Samir MA, Omar AF, et al. Synthesis of new pyrimidine derivatives and their antiproliferative activity against selected human cancer cell lines. Res Chem Intermed 2015;41:1789–801.
   Web of Science ®Google Scholar
• Narwal S, Kumar S, Verma PK. Design, synthesis and antimicrobial evaluation of pyrimidin-2-ol/thiol/amine analogues. Chem Cent J 2017;11:52–61.
   PubMedGoogle Scholar
• Al-Hazam HA, Al-Shamkani ZA, Al-Masoudia NA, et al. New chalcones and thiopyrimidine analogues derived from mefenamic acid: microwave-assisted synthesis, anti-HIV activity and cytotoxicity as antileukemic agents. Z Naturforsch 2017;72:1–8.
   Google Scholar
• Al-Masoudi NA, Kadhim RA, Abdul-Rida NA, et al. New biaryl-chalcone derivatives of pregnenolone via Suzuki–Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study. Steroids 2015;101:43–50.
   PubMed Web of Science ®Google Scholar
• Amor EC, Villasenor IM, Antemano R, et al. Cytotoxic C-methylated chalcones from Syzygium samarangense. Pharm Biol 2007;45:777–83.
   Web of Science ®Google Scholar
• Zhang EH, Wang RF, Guo SZ, et al. An update on antitumor activity of naturally occurring chalcones. J Evid Based Complement Altern Med 2013;2013:1–22.
   Google Scholar
• Peng F, Meng CW, Zhou QM, et al. Cytotoxic evaluation against breast cancer cells of isoliquiritigenin analogues from Spatholobus suberectus and their synthetic derivatives. J Nat Prod 2016;79:248–51.
   PubMed Web of Science ®Google Scholar
• Ahmed FF, Abd El-Hafeez AA, Abbas SH, et al. New 1,2,4-triazole-chalcone hybrids induce caspase-3 dependent apoptosis in A549 human lung adenocarcinoma cells. Eur J Med Chem 2018;151:705–22.
   PubMed Web of Science ®Google Scholar
• Lamie PF, Philoppes JN. Design and synthesis of three series of novel antitumor – azo derivatives. Med Chem Res 2017;26:1228–40.
   Google Scholar
• Philoppes JN, Lamie PF. Design and synthesis of new benzoxazole/benzothiazole-phthalimide hybrids as antitumor-apoptotic agents. Bioorg Chem 2019;89:102978–91.
   PubMed Web of Science ®Google Scholar
• Molinspiration Cheminformatics. Nova ulica, SK-900 26 Slovensky Grob, Slovak Republic. Available from: http://www.molinspiration.com/.
   Google Scholar
• PreADMET is a web-based application for predicting ADME data and building drug-like library using in silico method. Available from: https://preadmet.bmdrc.kr/.
   Google Scholar
• Stefani HA, Oliveira CB, Almeida RB, et al. Dihydropyrimidin-(2H)-ones obtained by ultrasound irradiation: a new class of potential antioxidant agents. Eur J Med Chem 2006;41:513–8.
   PubMed Web of Science ®Google Scholar
• Walters WP, Ajay , Murcko MA. Recognizing molecules with drug-like properties. Curr Opin Chem Biol 1999;3:384–7.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Younes A. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. Expert Opin Investig Drugs 2013;22:775–85.
   PubMed Web of Science ®Google Scholar